Peter Pemberton-Ross

Has grant

Head, HE & HTA Strategy

Switzerland

Research Interests

Explore related searches

Professors in Switzerland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Peter Pemberton-Ross is the Head of HE & HTA Strategy at Biogen in Switzerland. His research primarily focuses on cost-effectiveness models and health outcomes related to Alzheimer's disease and other neurological conditions. Recent publications include topics such as predicted clinical outcomes for treatments of Friedreich Ataxia and the fiscal impact of Alzheimer's disease in Germany. He also addresses challenges in demonstrating the value of disease-modifying therapies and has contributed to various predictive modeling studies.

Recent Grants

Grant: Close

Malaria modelling for near-elimination scenarios

Open Date:

Close Date:

Articles (12)

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (4)

Sandar Aye

Karolinska Institutet

SWEDEN

View details

Ron Handels

University of Maastricht

NETHERLANDS

View details

Maria Svensson

Uppsala University

SWEDEN

View details

Linus Jönsson

Karolinska Institutet

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Peter Pemberton-Ross

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (12)

IPECAD Modeling Workshop 2023 Cross Comparison Challenge on Cost-Effectiveness Models in Alzheimer’s Disease

CO197 Predicted Clinical Outcomes for Patients Treated With Omaveloxolone for Friedreich Ataxia

MSR104 Deriving Caregiver Health Utilities from Patient Endpoints: A Predictive Modelling Approach Using Real-World Survey Data

MSR136 IPECAD Modeling Workshop 2023 Cross Comparison Challenge on Cost-Effectiveness Models in Alzheimer's Disease and Related Dementias

Evaluation of the Fiscal Costs and Consequences of Alzheimer's Disease in Germany: Microsimulation of Patients' and Caregivers' Pathways.

Estimating Progression Rates Across the Spectrum of Alzheimer's Disease for Amyloid-Positive Individuals Using National Alzheimer's Coordinating Center Data.

Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer's Disease.

Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden

Challenges in demonstrating the value of disease-modifying therapies for Alzheimer’s disease

Estimation of the increased risk associated with recurrent events or polyvascular atherosclerotic cardiovascular disease in the United Kingdom.

PBI10 Cost Effectiveness Analysis for the Treatment of Psoriasis: The Use of Adalimumab Biosimilars

PND5 Predicted Delays in Dementia Onset for an Innovative Therapy Acting on Beta-Amyloid in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease

Collaborators (4)

Sandar Aye

Ron Handels

Maria Svensson

Linus Jönsson

Make your next move.